Dr. Frank Peacock and Dr. Damon R. Kuehl join BioTalk for a focused discussion on one of emergency medicine’s most persistent challenges: accurately diagnosing and predicting outcomes in mild traumatic brain injury. As Scientific Advisory Board members for BrainBox Solutions, Inc., they walk through what happens when a patient presents to the emergency department after a fall or sports injury and why current tools, including CT scans, often leave clinicians without clear answers. The conversation explores the gap between a “normal” scan and ongoing symptoms, and what missed or uncertain diagnoses can mean for patients weeks later.
Dr. Peacock outlines the HeadSMART II study and explains why combining blood biomarkers with neurocognitive testing provides a more complete assessment than biology alone. Dr. Kuehl discusses how multi-modal data, integrated through artificial intelligence, can generate an objective score to support real-time clinical decision-making and help identify patients at risk for persistent symptoms. The episode also highlights BrainBox’s leadership, including CEO Donna Edmonds, a member of the BioHealth Innovation Board of Directors, and the company’s role in advancing objective mTBI testing.
Listen now via your favorite podcast platform:
Apple: https://apple.co/4aiigz6
Spotify: https://bit.ly/4rZQWf7
iHeart: https://ihr.fm/3ZAGiPL
Amazon Podcasts: https://amzn.to/4bY0Fha
YouTube Music: https://bit.ly/4aF6SMB
TuneIn: https://bit.ly/4rXcx7V
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Dr. W. Frank Peacock IV is Professor of Emergency Medicine at Baylor College of Medicine. Chief Medical Officer at AseptiScope, and the founder of both a contract research organization called Comprehensive Research Associates, LLC and a medical education company named Emergencies in Medicine, LLC. Dr. Peacock received his medical degree from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital. He has >900 peer reviewed publications and is also the co-editor of multiple medical textbooks on heart failure, acute coronary syndromes, and traumatic brain injury.
Dr. Damon R. Kuehl is the Vice Chair of Research and Academic Affairs and Professor in the Department of Emergency Medicine at Virginia Tech, School of Medicine. He completed Medical School at University of Minnesota Medical School and his Emergency Medicine Residency at Stanford University. He has also completed residencies in Preventive Medicine and a Research Fellowship in the Center for Policy and Research in Emergency Medicine, at Oregon Health and Science University. Dr. Kuehl’s research primarily focuses on diagnostic and prognostic uncertainty in brain injury. He is a lead investigator for HeadSMART II and for HeadSMART Geriatrics, a NINDS funded 3 year study to develop a diagnostic tool for head trauma in older adults. He is the founder of the Carilion Brain Injury Center and also an investigator with the Virginia Tech Center for Biomechanics studying the boundary conditions associated with injuries in older adult falls.
This episode of the BioTalk with Rich Bendis Podcast brings together leaders from industry, academia, and economic development to unpack the vision behind a new life sciences Innovation District anchored in Prince William County. With introductions to NAUGEN, George Mason University’s Institute for Biohealth Innovation, and the Prince William County Department of Economic Development, setting the stage for how each organization contributes to the district’s foundation. The guests discuss the life science assets, research strengths, and translational capabilities that define the district and explain why it is well-positioned to support biotechnology and advanced R&D companies.
Secretary Juan Pablo Segura joins BioTalk for a conversation about Virginia’s growing position in the biohealth economy and the statewide strategy behind it. He outlines the significance of the new partnership with AstraZeneca, Lilly, and Merck, including up to $120 million in private investment to create a workforce development center and expand the Commonwealth’s life sciences capacity. Segura talks through how Virginia approaches company recruitment, what investors are responding to, and why the state is seeing increased interest from biomanufacturing and advanced R&D companies. He also discusses Virginia’s use of public-private partnerships to accelerate industry growth, strengthen the talent pipeline, and support emerging hubs across the Commonwealth. The conversation closes with a look at Virginia’s role in the BioHealth Capital Region and how the regional identity helps amplify the state’s message as it continues building a competitive biohealth ecosystem.
Getting a biotech company off the ground takes more than science; it takes strategy, funding, and the right network. 
In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company’s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen’s unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen’s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland’s BioHealth Capital Region has supported the company’s innovation and growth.
